Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to assess the efficacy and safety of nemolizumab after a
16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic
dermatitis (AD) not adequately controlled with topical treatments.